
EIT Pharma to Showcase Lonafarnib Data at Delta Cure Meeting in Milan
EIT Pharma will unveil new clinical data on lonafarnib, an experimental oral treatment for chronic hepatitis delta, at the 5th Delta Cure International Meeting in Milan on October 15-16. The presentations center on findings from the phase 3 D-LIVR trial, which evaluated the drug’s impact on liver health and viral suppression.



























